Friday, July 10, 2015 2:50:42 PM
One reason to R/S is that providers might be more comfortable taking higher priced shares -- so, at a lesser discount -- although the chart will still look abysmal.
However, another poster indicated he received a message from executive management that they would not R/S unless it was the last thing to do prior to an uplisting. In which case, R/S very unlikely as the company has very little likelihood of meeting the financial requirements for an uplisting.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM